Digital Therapeutics (DTx) Regulatory Pathway Guide (2026): FDA, EU MDR, DiGA & Global Approval

What Are Digital Therapeutics?

Digital therapeutics (DTx) are evidence-based therapeutic interventions driven by high-quality software programs to prevent, manage, or treat medical disorders or diseases. Unlike general wellness apps, DTx products:

• Treat specific diagnosed medical conditions with measurable clinical outcomes
• Require clinical evidence demonstrating safety and efficacy through rigorous trials
• Undergo regulatory review and are classified as medical devices requiring FDA clearance, CE marking, or equivalent authorization
• Deliver therapeutic interventions directly through software — cognitive behavioral therapy, neurobehavioral training, exposure therapy, or other evidence-based methodologies

DTx represent a convergence of software engineering, clinical science, and regulatory strategy. The market has matured rapidly: by 2025, dozens of DTx products are in use globally, treating conditions from addiction to ADHD, chronic insomnia, depression, anxiety, and chronic pain.

DTx vs. General Wellness Apps vs. Clinical Decision Support

Understanding the boundary between regulated DTx and unregulated software is critical:

Characteristic	General Wellness App	Clinical Decision Support (CDS)	Digital Therapeutic (DTx)
Intent	Wellness, fitness, general health	Support HCP decision-making	Treat, manage, or prevent a specific disease
Claims	No disease-specific claims	Provides recommendations to HCPs	Specific therapeutic indication
Evidence	Not required	Varies	RCT or equivalent clinical trial required
Regulation	Not a medical device (per FDA 2026 guidance)	May be excluded per 21st Century Cures Act CDS criteria	Regulated as a medical device

In January 2026, the FDA issued updated final guidance on both Clinical Decision Support software and General Wellness products. The revised General Wellness guidance expanded the category of products that may be considered non-devices, now allowing certain non-invasive wearables that measure parameters like blood pressure and glucose for general wellness purposes without FDA review. The CDS guidance narrowed the scope of software regulated as a device, introducing enforcement discretion for CDS functions providing a single clinically appropriate recommendation.

FDA Regulatory Pathways for Digital Therapeutics

Device Classification

Most digital therapeutics are classified as Class II medical devices. However, the specific classification and pathway depends on the product:

Class	Risk Level	Regulatory Pathway	DTx Examples
Class I	Low risk	General controls; often exempt	Basic symptom trackers with minimal therapeutic claims
Class II	Moderate risk	510(k) or De Novo	Most current DTx (reSET, Somryst, EndeavorRx, SleepioRx)
Class III	High risk	PMA	Life-sustaining or novel high-risk interventions

The 510(k) Pathway

The 510(k) pathway is the most common route for DTx products seeking FDA clearance. You must demonstrate that your DTx is "substantially equivalent" to a legally marketed predicate device.

Key requirements:

• Same intended use as the predicate
• Similar technological characteristics, or different technology but same safety/effectiveness profile
• Evidence from bench testing, clinical studies, or both

DTx products cleared via 510(k):

• reSET (2017) — substance use disorder (Pear Therapeutics, now PursueCare)
• reSET-O (2018) — opioid use disorder (Pear Therapeutics, now PursueCare)
• Somryst (2020) — chronic insomnia (Pear Therapeutics)
• EndeavorRx (2020) — ADHD in children (Akili Interactive)
• Freespira (2018) — panic disorder and PTSD (Palo Alto Health Sciences)

The De Novo Pathway

The De Novo classification process is used for novel devices of low to moderate risk for which no legally marketed predicate exists. A granted De Novo request creates a new classification regulation that future devices can use as a predicate.

EndeavorRx was granted De Novo classification (DEN200026) in 2020, establishing a new product code (QFT) and regulation (21 CFR 882.5803) for "Digital therapy device for Attention Deficit Hyperactivity Disorder." This classification now serves as a predicate for future 510(k) submissions for ADHD digital therapeutics.

When to consider De Novo:

• No legally marketed predicate exists for your intended use
• Your device is first-of-its-kind in its therapeutic category
• The risk profile can be managed with general and/or special controls

The PMA Pathway

PMA is reserved for Class III devices and is rarely used for DTx. It requires extensive clinical data, typically from pivotal clinical trials, and involves a more rigorous review process.

FDA Digital Health Center of Excellence

The FDA's Digital Health Center of Excellence (DHCoE) coordinates the agency's digital health efforts. While the Pre-Cert (Precertification) pilot program did not result in a standalone pathway, the insights from the program informed the FDA's current approach to AI/ML-enabled devices and software lifecycle management. The FDA's FY2026 guidance agenda includes forthcoming guidance on "Artificial Intelligence-Enabled Device Software Functions" and "Clinical Evidence Considerations for Digital Mental Health Treatment Devices."

EU Regulatory Framework

EU MDR Classification

Under EU MDR 2017/745, DTx products meeting the Article 2(1) definition of a medical device — software that diagnoses, monitors, predicts, or treats a condition in specific patients — must navigate classification and conformity assessment before receiving CE marking.

Most DTx are classified under Rule 11 (Software MDR classification):

• Class IIa: Software intended to provide information used to take decisions with diagnosis or therapeutic purposes — most monitoring and triage DTx
• Class IIb: Software that may cause serious impact on the patient or surgery — DTx that directly control treatment delivery or dosage
• Class III: Software where decisions can cause death or irreversible deterioration — rare for current DTx products

The EU MDR 2026 amendments are described by industry experts as the most consequential shift in European medical device regulation since the original MDR 2017/745 entered application, particularly for SaMD and DTx products.

EU AI Act Implications

The EU AI Act, which became applicable in phases starting 2024-2025, establishes the first comprehensive regulatory framework classifying certain medical AI systems as "high-risk." DTx incorporating AI/ML may face additional conformity assessment requirements beyond standard MDR obligations, including:

• Risk management system documentation specific to AI
• Data governance requirements for training datasets
• Technical documentation for AI system transparency
• Human oversight measures
• Accuracy, robustness, and cybersecurity requirements
• Post-market monitoring for AI system performance

Germany's DiGA Program

Germany pioneered DTx reimbursement through the Digital Care Act (DVG), passed in December 2019. The DiGA (Digitale Gesundheitsanwendungen) program allows physicians and psychotherapists to prescribe approved digital health applications to the approximately 73 million people covered by statutory health insurance.

How DiGA Works

The BfArM (Federal Institute for Drugs and Medical Devices) administers the DiGA directory and assessment process. As of March 2026, BfArM had received 247 total applications (189 for provisional listing, 58 for final listing).

Eligibility requirements:

• Classified as a Class I or IIa medical device under MDR (expanding to Class IIb in 2026)
• CE marked
• Primary therapeutic function delivered through digital technology
• Demonstrated positive healthcare effect (medical benefit or patient-relevant process improvement)
• Data protection and security compliance (GDPR, ISO 27001)
• Interoperability with German healthcare IT infrastructure

The DiGA Fast-Track Process

1. CE marking: Obtain MDR conformity assessment and CE mark
2. Application to BfArM: Submit comprehensive documentation covering ~120 technical, data protection, and clinical criteria
3. Provisional listing (12 months): Products with preliminary evidence can be listed in the DiGA directory while conducting clinical studies
4. Evidence generation: Conduct a clinical study (preferably an RCT) demonstrating positive healthcare effect during the provisional period
5. Final listing: Products meeting all evidence requirements receive permanent listing

2026 Changes to DiGA

Major changes effective February 2026:

• Class IIb devices eligible: Higher-risk DTx (including complex telemonitoring and remote monitoring) can now qualify as DiGA, with stricter evidence requirements including prospective comparative studies
• Outcome-based pricing: At least 20% of a DiGA's reimbursement price must be linked to performance-based success metrics, with mandatory "accompanying success measurement" (Begleitende Erfolgsmessung) reporting usage behavior, patient satisfaction, and dropout rates
• EU AI Act compliance: DiGA subject to the EU AI Act must declare conformity with AI Act provisions when applying for listing
• Real-world evidence: New requirements for ongoing structured reporting on usage behavior, patient satisfaction, and adherence

France and Other European Markets

France is developing its own DTx pathway (PECAN — Parcours de Soins en Applications Numériques), a pilot program running November 2025 to October 2026. Belgium has the mHealth Belgium system enabling reimbursement through a multi-level approval process. The UK MHRA's Software and AI Change Programme is shaping post-Brexit DTx regulation.

Approved DTx Products: A Quick Reference

Product	Indication	Regulatory Pathway	Year	Market
reSET	Substance use disorder	FDA 510(k)	2017	US
reSET-O	Opioid use disorder	FDA 510(k)	2018	US
Freespira	Panic disorder, PTSD	FDA 510(k)	2018	US
EndeavorRx	ADHD in children 8-12	FDA De Novo	2020	US
Somryst	Chronic insomnia	FDA 510(k)	2020	US
NightWare	PTSD-related nightmares	FDA De Novo	2020	US
RelieVRx	Chronic low back pain	FDA 510(k)	2021	US
Stanza	Fibromyalgia	FDA 510(k)	2023	US
SleepioRx	Chronic insomnia	FDA 510(k)	2023	US
DaylightRx	Generalized anxiety disorder	FDA 510(k)	2023	US
Rejoyn	Major depressive disorder	FDA 510(k)	2024	US
MamaLift Plus	Postpartum depression	FDA 510(k)	2024	US

Note: Pear Therapeutics, a DTx pioneer, filed for Chapter 11 bankruptcy in April 2023. Its reSET and reSET-O products were acquired by PursueCare in December 2023 and re-released in 2024. The DTx industry continues to mature despite individual company setbacks.

Clinical Evidence Requirements

FDA Expectations

The FDA's Digital Health Center of Excellence has established increasingly rigorous standards for DTx evidence generation:

• Clinical meaningfulness: Trials must demonstrate not only statistical significance but also clinical meaningfulness through improvements in how patients feel, function, or survive
• Function-based endpoints: FDA prioritizes objective outcome measures — validated performance tests, clinician-rated scales, and biomarkers — over patient-reported outcomes alone
• Durability of effect: Extended follow-up periods beyond the active intervention phase are increasingly expected
• Safety monitoring: Comprehensive adverse event tracking appropriate to the condition being treated

EU/DiGA Evidence Standards

For DiGA listing, manufacturers must demonstrate at least one positive healthcare effect (positive Versorgungseffekt, pVE), which can be either:

• Medical benefit (medizinischer Nutzen, mN): Direct improvement in health outcomes
• Patient-relevant structural/process improvement (patientenrelevante strukturelle und verfahrenstechnische Verbesserung, pSVV): Improvement in care delivery that benefits patients

In practice, BfArM strongly prefers RCTs, and virtually all successful DiGA applications have used randomized controlled trial designs.

Reimbursement Landscape

United States

In the CY 2026 Medicare Physician Fee Schedule Final Rule (published November 2025), CMS expanded HCPCS codes G0552, G0553, and G0554 to include digital mental health treatment (DMHT) devices classified under 21 CFR 882.5803 (digital therapy device for ADHD), in addition to devices already covered under 21 CFR 882.5801. These HCPCS codes cover the supply of DMHT devices and associated education, onboarding, and treatment management services when furnished incident to professional behavioral health services.

Additionally, Category III CPT codes exist for virtual reality-based therapy:

• 0770T: Virtual reality technology to assist therapy
• 0771T: Virtual reality procedural product

Coverage varies by payer. Many DTx manufacturers are pursuing value-based care arrangements with health plans, particularly for substance use disorder and mental health applications.

Germany

DiGA pricing: the manufacturer sets an initial price, which is then negotiated with the National Association of Statutory Health Insurances (GKV-SV) after 12 months. From 2026, at least 20% of remuneration must be linked to performance-based metrics.

Emerging Markets

Japan's PMDA "DASH for SaMD" accelerated review pathway, Health Canada's evolving digital health framework, and Australia's TGA software regulation all offer emerging opportunities for DTx market access.

Strategic Considerations for DTx Developers

Three Market Entry Strategies

Industry analysts identify three distinct strategies emerging among DTx companies:

1. Innovation-First: Target US and UK markets first, leveraging FDA PCCP and sandbox mechanisms. Accepts regulatory debt for speed to market.
2. Global-Ready: Design for Japan/EU stringency from inception to compress time-to-global-market. Higher upfront investment but broader access.
3. Market-Specific: Optimize for a single region, accepting delayed or foregone multi-market entry. Lower cost but limited scale.

Key Success Factors

• Treat regulatory architecture as competitive advantage — companies that build compliance into their product development lifecycle outperform those that bolt it on afterward
• Plan evidence generation early — design your clinical trial strategy before writing code, not after
• Build for interoperability — connection to electronic health records and healthcare IT systems is increasingly required for reimbursement
• Plan for AI regulation — if your DTx incorporates adaptive algorithms, prepare for EU AI Act compliance from the start
• Design real-world evidence collection into the product — post-market surveillance and outcomes data collection will be increasingly required for both regulatory compliance and reimbursement

What's Changing in 2026

Several regulatory developments make 2026 a pivotal year for DTx:

• FDA guidance on digital mental health devices: The FDA plans to issue "Clinical Evidence Considerations for Digital Mental Health Treatment Devices, including Computerized Behavioral Therapy Devices" — potentially the most significant DTx-specific guidance to date
• DiGA expansion to Class IIb: Germany opens its reimbursement program to higher-risk digital therapeutics
• Outcome-based DiGA pricing: 20% of reimbursement now tied to demonstrated performance
• EU AI Act enforcement milestones: High-risk AI systems (including some DTx) face increasing compliance deadlines
• CMS DTx reimbursement expansion: HCPCS codes G0552–G0554 expanded to cover ADHD digital therapeutics under the CY 2026 Medicare Physician Fee Schedule
• FDA AI-enabled device guidance: Forthcoming guidance on lifecycle management for AI-enabled device software functions will affect DTx products incorporating adaptive algorithms